Expanding into Europe is a milestone for many pharmaceutical companies, offering access to one of the world’s largest healthcare markets. However, Europe is not a single, homogenous entity—it’s a patchwork of countries, each with unique regulatory requirements, pricing strategies, and market opportunities. A well-planned, localized approach is critical to succeed. Here’s a breakdown of some…

In the competitive world of prescription-only medicine (POM), brand positioning is crucial. It’s not just about having an effective treatment—it’s about ensuring your product stands out to healthcare professionals (HCPs), patients, and stakeholders. At Elliogen, we specialize in helping pharmaceutical companies develop tailored brand strategies that resonate and drive success. Why Brand Positioning Matters Trust…

Navigating the complexities of the French pharmaceutical market can be daunting for U.S. companies aiming to expand their operations internationally. This is particularly true given the stringent regulatory, safety, and quality standards that France enforces. Understanding the role and advantages of an ‘Exploitant’—a mandatory local representative for pharmaceutical companies—is crucial for any U.S. entity looking…

Introducing a pharmaceutical product into the European Union (EU) necessitates a thorough understanding of the regulatory pathways for obtaining marketing authorization. This is a critical step for pharmaceutical companies aiming to successfully navigate the complex regulatory framework of the EU. There are two principal pathways to consider: the Centralised Procedure (CP) and the Decentralised Procedure…

Early Access Programs (EAPs) are a crucial aspect of the pharmaceutical landscape, providing a pathway for patients with serious or life-threatening conditions to access investigational drugs prior to official approval. For pharmaceutical companies, understanding and effectively managing EAPs can be a game-changer. This blog post will delve into what EAPs entail and how pharmaceutical companies…

The French healthcare system offers a unique framework for prescription drugs, impacting pharmaceutical companies, prescribers, and patients alike. As a pharmaceutical company looking to operate in France, it’s crucial to understand the dynamics between branded and generic medicines, patient preferences, and the implications of the ‘non substitutable’ rule. This understanding is key to developing effective…

The French healthcare system, renowned for its efficiency and universal coverage, presents a unique landscape for pharmaceutical companies looking to expand their market reach. As a pharmaceutical company exploring opportunities in France, it’s imperative to understand the intricacies of the French healthcare insurance system. This system’s structure and operations significantly impact drug pricing, reimbursement, and…

The French oncology sector, renowned for its advanced cancer treatment and research facilities, presents a wealth of opportunities for pharmaceutical companies and Contract Research Organizations (CROs) aiming to enter or expand their presence in the French market. This blog post delves into the main cancer centers in France and the current trends, with a focus…

Why Expanded Access is a Game-Changer in Pharma In the dynamic world of pharma and biotech, the spotlight is increasingly on EAP. These programs are not just about bringing medicines to market; they are about bringing hope to patients facing serious or life-threatening diseases. With information more accessible than ever, patients and advocates worldwide are…